Hemophilia Market Size Worth $18.1 Billion By
The global hemophilia market size is anticipated to value USD 18.1 billion until 2027. It is also expected to register a
CAGR of 5.5% over the forecasted years, 2020 to 2027. Rising awareness about immediate diagnosis & treatment of
diseases and favorable governing policies is projected to propel the market growth.
Hemophilia of type A is most commonly seen across the globe and is expected to be four times prevalent than type B.
On the other hand, type B hemophilia is projected to witness the fastest growth over the forecasted period, 2020 to
2027 owing to the presence of powerful pipeline products.
In 2019, the on-demand treatment segment dominated the global market. The segment of prophylaxis is projected to
witness the fastest growth in the upcoming years across the global market on account of its salient features like
reduction in the productivity loss that can guarantee good life outcomes.
North America accounted for the highest share of around 44.4% across the global market in 2019 due to the rising
inclination towards the prophylaxis medical treatment among the millennial population residing in this region. The Asia
Pacific is expected to witness the fastest growth in the upcoming years owing to the surge in per capita usage of
therapies for catering to factors VIII & IX deficiencies prevailing among citizens of countries like China, Japan, and India.
The hemophilia market across the globe includes key players such as Octapharma AG, Pfizer Inc., CSL Behring, Novo
Nordisk A/S., Bayer AG, Spark Therapeutics Inc., and Genzyme Corporation. Acquisitions, mergers and regional
expansions are generally undertaken by these players for widening their product portfolio and global reach.
Request Sample Copy of This Market Research @
“The global hemophilia market size is anticipated to value USD 18.1 billion until 2027. It